← Back to Search

Monoclonal Antibodies

LY3972406 Dose 2 for Plaque Psoriasis

Phase 2

Recruiting

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Are able to swallow oral medication

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 12

Awards & highlights

Study Summary

This trial is testing a medication called LY3972406 to see if it works and is safe for adults with a skin condition called plaque psoriasis.

Who is the study for?

This trial is for adults who've had moderate-to-severe chronic plaque psoriasis for at least 6 months. Participants must be able to swallow pills, allow blood sampling, and agree to skin biopsies. It's not open to those with other skin conditions or autoimmune diseases, active infections, or women who are breastfeeding.Check my eligibility

What is being tested?

The study is testing the effectiveness and safety of a new medication called LY3972406 compared to a placebo in treating plaque psoriasis. Participants will randomly receive either the actual drug or a placebo without knowing which one they're getting.See study design

What are the potential side effects?

While specific side effects of LY3972406 aren't listed here, common side effects from medications treating psoriasis may include irritation at the application site, headaches, fatigue, nausea and potential impacts on liver function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can take pills by mouth.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI 75)

Secondary outcome measures

Mean Change from Baseline in Body Surface Area (BSA)

Mean Change from Baseline in Dermatology Life Quality Index (DLQI)

Pharmacokinetics (PK): Plasma Concentration of LY3972406

Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: LY3972406 Dose 2Experimental Treatment1 Intervention

Participants will receive an oral dose of LY3972406

Group II: LY3972406 Dose 1Experimental Treatment1 Intervention

Participants will receive an oral dose of LY3972406

Group III: PlaceboPlacebo Group1 Intervention

Participants will receive placebo.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,620 Previous Clinical Trials

3,216,524 Total Patients Enrolled

Study DirectorEli Lilly and Company

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which specific criteria must individuals meet to be eligible for participation in this medical study?

"To be eligible for this research study, potential participants must have a diagnosis of plaque psoriasis and fall within the age range of 18 to 75. The trial aims to recruit a total of 75 individuals with these specific criteria."

Answered by AI

Is there an age restriction for potential participants, specifically targeting individuals above 45 years old?

"Patients aged 18 and above but under the age of 75 are eligible for recruitment in this trial."

Answered by AI

Can you provide information about the multiple facilities within the city that are currently conducting this clinical trial?

"A total of 17 clinical trial sites, including Conquest Research in Winter Park, Center for Clinical Studies in Houston, and Oregon Dermatology and Research Center in Portland, are currently offering enrollment opportunities. Additionally, there are several other locations available as well."

Answered by AI

Has the Food and Drug Administration officially authorized the use of Dose 1 of LY3972406?

"Considering that this is a Phase 2 trial for LY3972406 Dose 1, our team at Power rates its safety as a 2. While there is some existing data supporting safety, no evidence of efficacy has been established yet."

Answered by AI

Are there current opportunities for patient enrollment in this clinical trial?

"According to the information provided by clinicaltrials.gov, this particular study is not currently seeking participants. Despite that, there are currently 163 other trials actively enrolling patients at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

2023. "A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06176768.

All > High Point > Greensboro